Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $92.95, while Regeneron Pharmaceuticals Inc trades at $794 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | REGN | |
|---|---|---|
52-Week High | $97.99 | $812.27 |
52-Week Low | $92.76 | $545.94 |
Market Cap | — | $83.19B |
Sector | — | Health |
Enterprise Value | — | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF (iShares 7-10 Year Treasury Bond ETF) trades at $93.17 with minimal daily movement (+0.24%). Technical indicators show a neutral to bearish bias with moving averages signaling caution. The ETF maintains consistent dividend distributions, with recent payments of $0.31-$0.32 per share. Market focus remains on Treasury yield movements influenced by inflation data and Middle East tensions affecting oil prices.
Outlook remains tied to interest rate expectations and inflation trends. Recent institutional accumulation by Bank of America and Ferguson Shapiro provides support, but rising Treasury yields pose headwinds. Key risks include Federal Reserve policy shifts and geopolitical volatility impacting bond markets.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
